• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Q3 Results Will Impact Liquidia (LQDA) Investors

    Simply Wall St·11/14/2026 06:18:16
    Listen to the news
    • Liquidia reported Q3 2026 results on November 10, 2026, with revenue of US$225.3 million and a net loss of US$236.33 million, or a basic loss of US$2.64 per share from continuing operations.
    • The nine month figures show US$529.84 million in revenue alongside a US$108.74 million net loss, underscoring how Liquidia’s current commercial and development spending is weighing on profitability even as reported sales increase.
    • This article reviews how Liquidia’s sharp Q3 revenue and loss profile influences the investment narrative around pulmonary hypertension therapies.

    Scan Liquidia’s results in context by comparing its pulmonary hypertension story with 36 healthcare AI stocks that are also pouring cash into high-risk, high-reward treatment platforms.

    Liquidia Investment Narrative Recap

    To own Liquidia, you need to believe its pulmonary hypertension franchise can justify heavy spending and current losses. The analyst consensus Narrative on Simply Wall St leans on YUTREPIA prescription momentum, improving payer access and the potential for L606 to eventually share the same commercial and manufacturing backbone. The latest quarter, with high reported revenue but an even larger loss, highlights how dependent that belief is on execution.

    The sharp Q3 loss keeps the near term focus on two things. First, whether YUTREPIA vouchers and bridge programs convert into sustained, reimbursed use that supports cleaner revenue and cash generation. Second, whether investment in North Carolina capacity and the broader pipeline stretches the balance sheet before demand and L606 can help support it.

    The Q3 2026 earnings announcement is the key reference point right now. Management reported US$225.3 million of revenue alongside a net loss of US$236.33 million for the quarter, and a US$108.74 million loss over nine months on US$529.84 million of sales. That mix of scale and red ink brings the risk section of the analyst consensus Narrative on Simply Wall St into sharper focus for Liquidia.

    You are essentially watching three operational levers at once: payer terms and gross to net for YUTREPIA, the decision to build out manufacturing that could triple capacity, and the clinical and regulatory path for L606. If YUTREPIA pricing pressure persists or long term demand does not fill that extra capacity, the current loss profile could weigh on the story for longer.

    Liquidia's narrative projects US$942.5 million revenue and US$368.9 million earnings by 2029. This assumes 14.9% yearly revenue growth and an earnings increase of roughly US$463.1 million from current earnings of a US$94.2 million loss.

    Uncover why Liquidia's fair value indicates that Liquidia is roughly in line with its current price.

    NasdaqCM:LQDA 1-Year Stock Price Chart
    NasdaqCM:LQDA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One sharp contrast in the alternate Liquidia story is the concern that higher R&D and the US$380.7 million settlement could squeeze future earnings. The most cautious analysts were only penciling in about US$861.0 million of 2029 revenue and US$327.6 million of earnings before this Q3 release, which paints a much tougher road. That gap in expectations shows how far views can spread, so use this earnings update as a prompt to explore several investor narratives before deciding where you sit.

    Explore 4 other Liquidia fair value estimates, including one that suggests as much as 37% downside from the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.

    Looking for more Liquidia-sized investment ideas?

    If Liquidia has sharpened your appetite for deeper research, broaden your watchlist with companies filtered by the traits you care about most using the Simply Wall St Screener.